Molecular imaging in the clinical arena

JAMA

Volumn 293, Issue 7, 2005, Pages 855-862

  Jaffer, Farouc A ^a,b   Weissleder, Ralph ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE; ARCITUMOMAB; BECTUMOMAB; BOMBESIN; CAPROMAB; DOPAMINE RECEPTOR; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ESTROGEN RECEPTOR; FANOLESOMAB; FIBRIN; FIBRONECTIN; FLUORODEOXYGLUCOSE F 18; FLUOROTHYMIDINE F 18; FOLATE RECEPTOR; IRON OXIDE; LIPOCORTIN 5; MATRIX METALLOPROTEINASE; MEDRONIC ACID; METHOXY ISOBUTYL ISONITRILE TECHNETIUM TC 99M; MONOCLONAL ANTIBODY B.72.3; NUCLEAR MAGNETIC RESONANCE IMAGING AGENT; OXIDIZED LOW DENSITY LIPOPROTEIN; SEROTONIN RECEPTOR; SOMATOSTATIN DERIVATIVE; SULESOMAB; SUPERPARAMAGNETIC IRON OXIDE; ULTRASMALL SUPERPARAMAGNETIC IRON OXIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VITRONECTIN RECEPTOR;

ATHEROSCLEROSIS; CANCER DIAGNOSIS; DIAGNOSTIC PROCEDURE; MEDICAL RESEARCH; MOLECULAR IMAGING; NON INVASIVE MEASUREMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; REVIEW;

EID: 13844265749     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.293.7.855     Document Type: Review

References (55)

1. Weissleder R, Mahmood U. Molecular imaging. Radiology. 2001;219:316-333.
2. Zerhouni E. Medicine: the NIH roadmap. Science. 2003;302:63-72.
3. Tempany CM, McNeil BJ. Advances in biomedical imaging. JAMA. 2001;285:562-567.
4. Jaffer FA, Weissleder R. Seeing within: molecular imaging of the cardiovascular system. Circ Res. 2004;94:433-445.
5. Ntziachristos V, Ripoll J, Weissleder R. Would near-infrared fluorescence signals propagate through large human organs for clinical studies? Opt Lett. 2002;27:333-335.
6. Funovics MA, Weissleder R, Mahmood U. Catheter-based in vivo imaging of enzyme activity and gene expression: feasibility study in mice. Radiology. 2004;231:659-666.
7. Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nat Med 2003;9:123-128.
8. InfraRedx technology development. Available at: http://www.infraredx.com/ technology.index.htm. Accessed January 20, 2005.
9. Ntziachristos V, Tung CH, Bremer C, Weissleder R. Fluorescence molecular tomography resolves protease activity in vivo. Nat Med 2002;8:757-760.
10. Lanza GM, Wickline SA. Targeted ultrasonic contrast agents for molecular imaging and therapy. Curr Probl Cardiol. 2003;28:625-653.
11. Lindner JR, Microbubbles in medical imaging: current applications and future directions. Nat Rev Drug Discov. 2004;3:527-532.
12. National Library of Medicine. PubChem. Available at: http://pubchem.ncbi. nlm.nih.gov/. Accessed December 29, 2004.
13. Weissleder R. Scaling down imaging: molecular mapping of cancer in mice. Nat Rev Cancer. 2002;2:11-18.
14. Harisinghani MG, Barentsz J, Hahn PF, et al. Noninvasive detection of clinically occult lymph-node metastases in prostate cancer. N Engl J Med. 2003;348:2491-2499.
15. Rudin M, Weissleder R. Molecular imaging in drug discovery and development. Nat Rev Drug Discov. 2003;2:123-131.
16. Aboagye EO, Luthra SK, Brady F, et al. Cancer Research UK procedures in manufacture and toxicology of radiotracers intended for pre-phase I positron emission tomography studies in cancer patients. Br J Cancer. 2002;86:1052-1056.
17. Massoud TF, Gambhir SS. Molecular imaging in living subjects: seeing fundamental biological processes in a new light. Genes Dev. 2003;17:545-580.
18. Blasberg RG, Tjuvajev JG. Molecular-genetic imaging: current and future perspectives. J Clin Invest. 2003;111:1620-1629.
19. Choudhury RP, Fuster V, Fayad ZA. Molecular, cellular and functional imaging of atherothrombosis. Nat Rev Drug Discov. 2004;3:913-925.
20. Humphrey LL, Teutsch S, Johnson M. Lung cancer screening with sputum cytologic examination, chest radiography, and computed tomography: an update for the US Preventive Services Task Force. Ann Intern Med. 2004;140:740-753.
21. Walsh JM, Terdiman JP. Colorectal cancer screening: scientific review. JAMA. 2003;289:1288-1296.
22. Fletcher SW, Elmore JG. Mammographic screening for breast cancer. N Engl J Med. 2003;348:1672-1680.
23. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the US Preventive Services Task Force. Ann Intern Med. 2002;137:917-929.
24. Weissleder R, Tung CH, Mahmood U, Bogdanov A Jr. In vivo imaging of tumors with protease-activated near-infrared fluorescent probes. Nat Biotechnol. 1999;17:375-378.
25. Tung CH, Mahmood U, Bredow S, Weissleder R. In vivo imaging of proteolytic enzyme activity using a novel molecular reporter. Cancer Res. 2000;60:4953-4958.
26. Bremer C, Tung CH, Weissleder R. In vivo molecular target assessment of matrix metalloproteinase inhibition. Nat Med. 2001;7:743-748.
27. Marten K, Bremer C, Khazale K, et al. Detection of dysplastic intestinal adenomas using enzyme-sensing molecular beacons in mice. Gastroenterology. 2002;122:406-414.
28. Kelly K, Alencar H, Funovics M, Mahmood U, Weissleder R. Detection of invasive colon cancer using a novel, targeted, library-derived fluorescent peptide. Cancer Res. 2004;64:6247-6251.
29. Joyce JA, Baruch A, Chehade K, et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell. 2004;5:443-453.
30. Ntziachristos V, Yodh AG, Schnall M, Chance B. Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement. Proc Natl Acad Sci U S A. 2000;97:2767-2772.
31. Taroni P, Pifferi A, Torricelli A, Comelli D, Cubeddu R. In vivo absorption and scattering spectroscopy of biological tissues. Photochem Photobiol Sci. 2003;2:124-129.
32. Boas DA, Dale AM, Franceschini MA. Diffuse optical imaging of brain activation: approaches to optimizing image sensitivity, resolution, and accuracy. Neuroimage. 2004;23(suppl 1):S275-S288.
33. Lardinois D, Weder W, Hany TF, et al. Staging of non-small-cell lung cancer with integrated positron-emission tomography and computed tomography. N Engl J Med. 2003;348:2500-2507.
34. Gambhir SS. Molecular imaging of cancer with positron emission tomography. Nat Rev Cancer. 2002;2:683-693.
35. West CM, Jones T, Price P. The potential of positron-emission tomography to study anticancer-drug resistance. Nat Rev Cancer. 2004;4:457-469.
36. Guller U, Nitzsche E, Moch H, Zuber M. Is positron emission tomography an accurate noninvasive alternative to sentinel lymph node biopsy in breast cancer patients? J Natl Cancer Inst. 2003;95:1040-1043.
37. Harisinghani MG, Weissleder R. Sensitive, noninvasive detection of lymph node metastases. PLoS Med. 2004;1:e66.
38. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer. 2002;38(suppl 5):S60-S65.
39. Koehne G, Doubrovin M, Doubrovina E, et al. Serial in vivo imaging of the targeted migration of human HSV-TK-transduced antigen-specific lymphocytes. Nat Biotechnol. 2003;21:405-413,
40. Divgi CR, Welt S, Kris M, et al. Phase I and imaging trial of indium 111-labeled anti-epidermal growth factor receptor monoclonal antibody 225 in patients with squamous cell lung carcinoma. J Natl Cancer Inst. 1991;83:97-104.
41. Burns HD, Hamill TG, Eng WS, Francis B, Fioravanti C, Gibson RE. Positron emission tomography neuroreceptor imaging as a tool in drug discovery, research and development. Curr Opin Chem Biol. 1999;3:388-394.
42. Smith-Jones PM, Solit DB, Akhurst T, Afroze F, Rosen N, Larson SM. Imaging the pharmacodynamics of HER2 degradation in response to Hsp90 inhibitors. Nat Biotechnol. 2004;22:701-706.
43. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation. 2003;108:1664-1672.
44. Chen J, Tung CH, Mahmood U, et al. In vivo imaging of proteolytic activity in atherosclerosis. Circulation. 2002;105:2766-2771.
45. Kooi ME, Cappendijk VC, Cleutjens KB, et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation. 2003;107:2453-2458.
46. Trivedi RA, U-King-Im JM, Graves MJ, et al. In vivo detection of macrophages in human carotid atheroma: temporal dependence of ultrasmall superparamagnetic particles of iron oxide-enhanced MRI. Stroke. 2004;35:1631-1635.
47. Hamilton AJ, Huang SL, Warnick D, et al. Intravascular ultrasound molecular imaging of atheroma components in vivo. J Am Coll Cardiol. 2004;43:453-460.
48. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule 1 expression using a novel multimodal nanoparticle. Available at: http://circres.ahajournals.org. Accessed January 25, 2005.
49. Kietselaer BL, Reutelingsperger CP, Heidendal GA, et al. Noninvasive detection of plaque instability with use of radiolabeled annexin A5 in patients with carotid-artery atherosclerosis. N Engl J Med. 2004;350:1472-1473.
50. 3-integrin-targeted nanoparticles. Circulation. 2003;108:2270-2274.
51. Matter CM, Schuler PK, Alessi P, et al. Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ Res. 2004;95:1225-1233.
52. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
53. Hofstra L, Liem IH, Dumont EA, et al. Visualisation of cell death in vivo in patients with acute myocardial infarction. Lancet 2000;356:209-212.
54. Narula J, Acio ER, Narula N, et al. Annexin-V imaging for noninvasive detection of cardiac allograft rejection. Nat Med. 2001;7:1347-1352.
55. Jaffer FA, Tung CH, Gerszten RE, Weissleder R. In vivo imaging of thrombin activity in experimental thrombi with thrombin-sensitive near-infrared molecular probe. Arterioscler Thromb Vasc Biol. 2002;22:1929-1935.